Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan R Brody

Showing results (91-100 of 170) with videos related to

Pageof 17
Sort By:
Cancer Biology & Therapy|August 28, 2010
CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapyYu-Hung Huang, Joseph A Cozzitorto, Nathan G Richards, et al.
Acta Biomaterialia|June 3, 2021
Gemcitabine-loaded microbubble system for ultrasound imaging and therapyLauren J Delaney, John R Eisenbrey, David Brown, et al.
Cancer Research|June 3, 2009
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinaseChristina L Costantino, Agnieszka K Witkiewicz, Yuki Kuwano, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 19, 2026
Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR InhibitionPaige C Arneson-Wissink, Katherine Pelz, Beth Worley, et al.
BMJ Open|October 17, 2023
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinomaFrancesca M Ponzini, Christopher W Schultz, Benjamin E Leiby, et al.
Cancer Research|February 28, 2016
Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor GrowthYu-Hung Huang, Weidan Peng, Narumi Furuuchi, et al.
The Journal of Biological Chemistry|April 13, 2012
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organizedChristopher C Valley, Andrew K Lewis, Deepti J Mudaliar, et al.
Journal of the American College of Surgeons|February 10, 2018
A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2Avinoam Nevler, Alexander J Muller, Joseph A Cozzitorto, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2022
Psychosocial distress is dynamic across the spectrum of cancer care and requires longitudinal screening for patient-centered careThomas L Sutton, Marina Affi Koprowski, Alison Grossblatt-Wait, et al.
Expert Opinion on Drug Delivery|March 6, 2010
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the futureShayna L Showalter, Sarah Charles, Justin Belin, et al.
Pageof 17

Showing results (91-100 of 170) with videos related to

Sort By:
Pageof 17
Cancer Biology & Therapy|August 28, 2010
CanScript, an 18-Base pair DNA sequence, boosts tumor cell-specific promoter activity: implications for targeted gene therapyYu-Hung Huang, Joseph A Cozzitorto, Nathan G Richards, et al.
Acta Biomaterialia|June 3, 2021
Gemcitabine-loaded microbubble system for ultrasound imaging and therapyLauren J Delaney, John R Eisenbrey, David Brown, et al.
Cancer Research|June 3, 2009
The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinaseChristina L Costantino, Agnieszka K Witkiewicz, Yuki Kuwano, et al.
Journal of Cachexia, Sarcopenia and Muscle|March 19, 2026
Impaired Adipose Anabolism in Pancreatic Cancer Cachexia Is Reversed by HuR InhibitionPaige C Arneson-Wissink, Katherine Pelz, Beth Worley, et al.
BMJ Open|October 17, 2023
Repurposing the FDA-approved anthelmintic pyrvinium pamoate for pancreatic cancer treatment: study protocol for a phase I clinical trial in early-stage pancreatic ductal adenocarcinomaFrancesca M Ponzini, Christopher W Schultz, Benjamin E Leiby, et al.
Cancer Research|February 28, 2016
Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor GrowthYu-Hung Huang, Weidan Peng, Narumi Furuuchi, et al.
The Journal of Biological Chemistry|April 13, 2012
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces death receptor 5 networks that are highly organizedChristopher C Valley, Andrew K Lewis, Deepti J Mudaliar, et al.
Journal of the American College of Surgeons|February 10, 2018
A Sub-Type of Familial Pancreatic Cancer: Evidence and Implications of Loss-of-Function Polymorphisms in Indoleamine-2,3-Dioxygenase-2Avinoam Nevler, Alexander J Muller, Joseph A Cozzitorto, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 28, 2022
Psychosocial distress is dynamic across the spectrum of cancer care and requires longitudinal screening for patient-centered careThomas L Sutton, Marina Affi Koprowski, Alison Grossblatt-Wait, et al.
Expert Opinion on Drug Delivery|March 6, 2010
Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the futureShayna L Showalter, Sarah Charles, Justin Belin, et al.
Pageof 17